BGNE - BeiGene, Ltd.
| Previous Close | 127.00 |
| Open | 127.28 |
| Bid | 120.18 x 800 |
| Ask | 180.00 x 1100 |
| Day's Range | 125.28 - 128.85 |
| 52 Week Range | 77.54 - 220.10 |
| Volume | 933,655 |
| Avg. Volume | 364,703 |
| Market Cap | 7.536B |
| Beta (3Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.11 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 198.95 |
- GlobeNewswire•3 days ago
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of preliminary clinical data from an ongoing Phase 1/2 trial of its investigational PARP inhibitor, pamiparib, in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory (R/R) glioblastoma multiforme (GBM). Discovered by BeiGene scientists in Beijing, pamiparib is currently in Phase 3 trials globally and in China as a monotherapy and in Phase 1/2 trials in combination with chemotherapy or immunotherapy for a variety of solid tumors. “There are limited treatment options available for patients with newly diagnosed and recurrent/refractory glioblastoma.
- Zacks•4 days ago
BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%
BeiGene (BGNE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- GlobeNewswire•4 days ago
Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that Center for Drug Evaluation of China’s National Medical Product Administration (NMPA, formerly known as CFDA) has granted priority review status to the New Drug Applications (NDAs) for the company’s investigational BTK inhibitor zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and for its investigational anti-PD-1 antibody tislelizumab in patients with R/R classical Hodgkin’s lymphoma (cHL). “We’re excited that the NDAs for both zanubrutinib and tislelizumab are receiving priority review by the NMPA,” commented Wendy Yan, Senior Vice President, Global Head of Regulatory Affairs at BeiGene.
- GlobeNewswire•6 days ago
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on November 9, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 52,230 American Depositary Shares to 154 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- PR Newswire•11 days ago
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
HKEX: 06160) in a Phase 1b clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati's sitravatinib in combination with BeiGene's investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors. The clinical trial is currently enrolling patients in China and Australia. BeiGene's ability to rapidly enroll patients into this clinical trial has the potential to significantly expand and accelerate our development efforts for sitravatinib and provide access to additional patient populations," said Charles Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati.
- Reuters•12 days ago
BRIEF-Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib
Nov 8 (Reuters) - Beigene Ltd: * BEIGENE INITIATES GLOBAL HEAD-TO-HEAD PHASE 3 CLINICAL TRIAL OF ZANUBRUTINIB Source text for Eikon: Further company coverage:
- GlobeNewswire•12 days ago
BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the first patient was dosed in a global Phase 3 clinical trial of its investigational BTK inhibitor zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “We continue to be encouraged by data on zanubrutinib in various B-cell malignancies and are excited to further expand the development program for zanubrutinib in CLL and SLL with this Phase 3 trial, which represents the second Phase 3 study directly comparing zanubrutinib to ibrutinib,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene.
- GlobeNewswire•12 days ago
BeiGene Reports Third Quarter 2018 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, Nov. 07, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•14 days ago
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
CAMBRIDGE, Mass. and BEIJING, China, Nov. 05, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Investing.com•17 days ago
China’s Innovent Extends Gain from Solid HK IPO
Investing.com - The shares of China’s Innovent Biologics Inc (HK:1801) continued to rise on Friday morning in Asia, two days after their initial public offering.
- GlobeNewswire•18 days ago
BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting
Company to Host Investor Meeting and Webcast on Monday, December 3, at 8 pm PST CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE), a.
- ACCESSWIRE•18 days ago
Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones ...
- Reuters•26 days ago
BRIEF-Beigene Announces Acceptance Of Its New Drug Application In China
Oct 24 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES ACCEPTANCE OF ITS NEW DRUG APPLICATION IN CHINA AND TOP-LINE PIVOTAL DATA FOR ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA ...
- GlobeNewswire•26 days ago
BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Zanubrutinib was discovered in BeiGene’s research facilities in Beijing, China, and is being developed globally by BeiGene as a monotherapy and in combination with other therapies to treat various hematologic malignancies.
- Reuters•28 days ago
BRIEF-Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors
Oct 22 (Reuters) - Beigene Ltd: * BEIGENE PRESENTS PRELIMINARY CLINICAL DATA ON PARP INHIBITOR PAMIPARIB IN COMBINATION WITH LOW-DOSE TEMOZOLOMIDE IN PATIENTS WITH SOLID TUMORS AT EUROPEAN SOCIETY FOR ...
- Zacks•28 days ago
BeiGene (BGNE): Moving Average Crossover Alert
BeiGene, Ltd. (BGNE) could be a stock to avoid from a technical perspective
- GlobeNewswire•28 days ago
BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that preliminary clinical data from an ongoing Phase 1 trial of its investigational PARP inhibitor, pamiparib, in combination with low-dose temozolomide in patients with locally advanced or metastatic solid tumors were presented at the European Society for Medical Oncology (ESMO) 2018 Congress, being held in Munich, Germany. Discovered by BeiGene scientists in Beijing, pamiparib is currently in Phase 3 trials globally and in China as a monotherapy and in Phase 1/2 trials in combination with chemotherapy or immunotherapy for a variety of solid tumors. “In prior non-clinical studies, pamiparib has been shown to not only inhibit PARP from repairing damaged DNA, but also trap PARP on DNA undergoing repair, which we believe furthers its potential for anti-tumor activity.
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Reuters•last month
BRIEF-Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
Oct 12 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES UPDATED RESULTS FROM PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA * BEIGENE LTD - FIRST U.S. NDA FILING FOR ...
- GlobeNewswire•last month
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Reuters•last month
BRIEF-MEI Pharma And Beigene Announce Clinical Collaboration
Oct 11 (Reuters) - Beigene Ltd: * MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES * MEI PHARMA INC - STUDY ...
- PR Newswire•last month
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies. "We are excited to be working with BeiGene to explore the potential of ME-401 in combination with zanubrutinib," said Robert Mass, M.D., chief medical officer of MEI Pharma.
- Reuters•last month
BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China
Oct 10 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES NATIONAL REIMBURSEMENT INCLUSION OF VIDAZA® (AZACITIDINE FOR INJECTION) BY THE STATE MEDICAL INSURANCE ADMINISTRATION IN CHINA * BEIGENE SAYS VIDAZA ...
- GlobeNewswire•last month
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China
BEIJING, China and CAMBRIDGE, Mass., Oct. 10, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•last month
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings
CAMBRIDGE, Mass. and BEIJING, China, Oct. 08, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
